IHS Chemical Week

Regions :: Middle East

Lonza Signs Manufacturing Deal with Immune Pharmaceuticals

12:04 AM MDT | July 19, 2011 | Deepti Ramesh

Lonza says it has signed an exclusive contract for the production of Immune Pharmaceuticals’ (Tel Aviv, Israel) human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility, under the terms of the deal. Immune is a biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing unmet medical needs in the treatment of cancer and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa